Cargando…
ERK5 Signalling and Resistance to ERK1/2 Pathway Therapeutics: The Path Less Travelled?
The RAS-regulated RAF-MEK1/2-ERK1/2 signalling pathway is frequently de-regulated in human cancer. Melanoma in particular exhibits a high incidence of activating BRAF(V600E/K) and NRAS(Q61L/K) mutations and such cells are addicted to the activity of these mutant oncoproteins. As a result three diffe...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315226/ https://www.ncbi.nlm.nih.gov/pubmed/35903549 http://dx.doi.org/10.3389/fcell.2022.839997 |